NYSE:SNN
Smith & Nephew PLC (SNN)
Financials 
Technical Analysis 
Jun 10, 2026, 12:00 amThis summary was created by AI, based on 4 opinions in the last 12 months.
Smith & Nephew PLC (SNN-N) has increasingly garnered positive reviews, particularly due to successful management changes over the past four years that have led to improved revenue, profitability, and brand recognition. Analysts highlight the company's strong position in the orthopedic market, offering joint repairs and dressings, and note that it's currently trading at approximately half the price of its chief competitor, Stryker. Many experts see a bright future for the stock, citing expected margin improvements and industry growth. As a UK company, it appears to be undervalued compared to similar firms, yet the recent changes in management and investments in R&D suggest potential for significant operational and stock price upside. There's a consensus among analysts that Smith & Nephew represents a compelling investment opportunity at present.
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
